Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.58
+2.3%
$5.02
$3.42
$7.20
$255.21M1.751.57 million shs708,073 shs
Aphria Inc. stock logo
APHA
Aphria
$15.38
$15.48
$2.78
$32.29
$4.87B2.6721.83 million shsN/A
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
$24.40
+0.2%
$23.30
$19.20
$25.83
N/AN/A127,565 shs112,684 shs
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$6.05
+0.5%
C$5.89
C$5.09
C$6.45
C$611.96M0.567,197 shs9,509 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%+10.24%-17.86%+14.09%-6.63%
Aphria Inc. stock logo
APHA
Aphria
0.00%0.00%0.00%0.00%0.00%
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
0.00%+1.92%+3.92%+17.11%+3.74%
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
+0.50%+5.22%+3.95%+3.24%+5.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2834 of 5 stars
0.01.00.00.02.10.80.6
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/AN/AN/AN/A
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
N/AN/AN/AN/AN/AN/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Aphria Inc. stock logo
APHA
Aphria
0.00
N/AN/AN/A
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
0.00
N/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
3.50
Strong BuyC$7.1518.18% Upside

Current Analyst Ratings Breakdown

Latest HIK, EVT, ACB, APHA, and GUD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetHold ➝ BuyC$6.50
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.04$0.62 per share7.43$7.78 per share0.59
Aphria Inc. stock logo
APHA
Aphria
$405.96M12.00$0.09 per share166.43$4.80 per share3.20
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
$495.20MN/AN/AN/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$348.70M1.75C$1.57 per share3.85C$7.65 per share0.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1141.5910.40N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Aphria Inc. stock logo
APHA
Aphria
-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/A
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
N/AN/A0.00N/AN/AN/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
-C$30.73M-C$0.30N/AN/A-8.81%-4.04%0.51%N/A

Latest HIK, EVT, ACB, APHA, and GUD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/A
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
$1.978.07%N/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
N/AN/AN/AN/AN/A

Latest HIK, EVT, ACB, APHA, and GUD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/2/2025
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
monthly$0.16468.1%7/15/20257/15/20257/31/2025
6/3/2025
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
monthly$0.16468.4%6/16/20256/16/20256/30/2025
5/2/2025
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
monthly$0.16468.7%5/15/20255/15/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Aphria Inc. stock logo
APHA
Aphria
0.25
2.36
1.17
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
N/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
7.52
3.36
1.79
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
Aphria Inc. stock logo
APHA
Aphria
1,200316.80 millionN/AOptionable
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
N/AN/AN/ANot Optionable
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
725101.15 millionN/ANot Optionable

Recent News About These Companies

Is Knight Therapeutics stock a buy?
Knight Therapeutics is a buy, Stifel says
Collective, Knight at 52-Week Highs on News
Sime Armoyan selling more Knight Therapeutics (GUD)
Endo divests Paladin business
Knight Therapeutics Inc. (GUD.TO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.58 +0.11 (+2.35%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$4.57 -0.01 (-0.22%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Aphria stock logo

Aphria NASDAQ:APHA

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Eaton Vance Tax-Advantaged Dividend Income Fund NYSE:EVT

$24.40 +0.06 (+0.25%)
As of 07/3/2025 03:30 PM Eastern

Eaton Vance Tax-Advantaged Dividend Income Fund is a closed-ended equity mutual fund launched and managed by Eaton Vance Management. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating across the diversified sectors. The fund primarily invests in dividend paying value stocks of companies that qualify for favorable federal income tax treatment. It benchmarks the performance of its portfolio against the Russell 1000 Value Index. Eaton Vance Tax-Advantaged Dividend Income Fund was formed on September 30, 2003 and is domiciled in the United States.

Knight Therapeutics stock logo

Knight Therapeutics TSE:GUD

C$6.05 +0.03 (+0.50%)
As of 07/4/2025 04:00 PM Eastern

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.